AN ACT ESTABLISHING THE STOP ADDICTION FRAUD ETHICS (SAFE) ACT OF 2023 AND AMENDING THE LAW REGARDING EARWAX REMOVAL BY AUDIOLOGISTS. SL 2023-141. Enacted October 20, 2023. Effective January 1, 2024.
STOP ADDICTION FRAUD ETHICS ACT OF 2023.
Printer-friendly: Click to view
View NCGA Bill Details | 2023-2024 Session |
AN ACT ESTABLISHING THE STOP ADDICTION FRAUD ETHICS (SAFE) ACT OF 2023 AND AMENDING THE LAW REGARDING EARWAX REMOVAL BY AUDIOLOGISTS.Intro. by Reeder, Chesser, K. Baker.
SOG comments (2):
Long title change
Amendment to the 3rd edition changed the long title. Original long title was AN ACT ESTABLISHING THE STOP ADDICTION FRAUD ETHICS (SAFE) ACT OF 2023.
Bill History:
-
Mon, 20 Mar 2023 House: Filed
-
Tue, 21 Mar 2023 House: Passed 1st Reading
-
Tue, 4 Apr 2023 House: Reptd Fav Com Substitute
-
Tue, 4 Apr 2023 House: Re-ref Com On Judiciary 1
-
Wed, 19 Apr 2023 House: Reptd Fav
-
Wed, 19 Apr 2023 House: Re-ref Com On Rules, Calendar, and Operations of the House
-
Tue, 25 Apr 2023 House: Reptd Fav
-
Tue, 25 Apr 2023 House: Cal Pursuant Rule 36(b)
-
Tue, 25 Apr 2023 House: Added to Calendar
-
Tue, 25 Apr 2023 House: Passed 2nd Reading
-
Tue, 25 Apr 2023 House: Passed 3rd Reading
-
Wed, 26 Apr 2023 House: Regular Message Sent To Senate
-
Wed, 26 Apr 2023 Senate: Regular Message Received From House
-
Wed, 26 Apr 2023 Senate: Passed 1st Reading
-
Wed, 26 Apr 2023 Senate: Ref To Com On Rules and Operations of the Senate
-
Mon, 12 Jun 2023 Senate: Withdrawn From Com
-
Wed, 14 Jun 2023 Senate: Reptd Fav
-
Wed, 14 Jun 2023 Senate: Re-ref Com On Judiciary
-
Thu, 22 Jun 2023 Senate: Reptd Fav Com Substitute
-
Thu, 22 Jun 2023 Senate: Com Substitute Adopted
-
Thu, 22 Jun 2023 Senate: Re-ref Com On Rules and Operations of the Senate
-
Mon, 11 Sep 2023 Senate: Withdrawn From Com
-
Mon, 11 Sep 2023 Senate: Placed On Cal For 09/12/2023
-
Tue, 12 Sep 2023 Senate: Withdrawn From Cal
-
Tue, 12 Sep 2023 Senate: Placed On Cal For 09/13/2023
-
Wed, 13 Sep 2023 Senate: Withdrawn From Cal
-
Wed, 13 Sep 2023 Senate: Placed On Cal For 09/19/2023
-
Mon, 18 Sep 2023 Senate: Withdrawn From Cal
-
Mon, 18 Sep 2023 Senate: Placed On Cal For 09/20/2023
-
Wed, 20 Sep 2023 Senate: Withdrawn From Cal
-
Wed, 20 Sep 2023 Senate: Placed On Cal For 09/21/2023
-
Thu, 21 Sep 2023 Senate: Withdrawn From Cal
-
Thu, 21 Sep 2023 Senate: Placed On Cal For 09/22/2023
-
Fri, 22 Sep 2023 Senate: Amend Adopted A1
-
Fri, 22 Sep 2023 Senate: Passed 2nd Reading
-
Fri, 22 Sep 2023 Senate: Passed 3rd Reading
-
Fri, 22 Sep 2023 Senate: Engrossed
-
Fri, 22 Sep 2023 Senate: Special Message Sent To House
-
Fri, 22 Sep 2023 House: Special Message Received For Concurrence in S Com Sub
-
Fri, 22 Sep 2023 House: Ref To Com On Rules, Calendar, and Operations of the House
-
Thu, 5 Oct 2023 House: Withdrawn From Com
-
Thu, 5 Oct 2023 House: Placed On Cal For 10/10/2023
-
Tue, 10 Oct 2023 House: Concurred In S Com Sub
-
Tue, 10 Oct 2023 House: Ordered Enrolled
-
Tue, 10 Oct 2023 House: Ratified
-
Tue, 10 Oct 2023 House: Pres. To Gov. 10/10/2023
-
Fri, 20 Oct 2023 House: Signed by Gov. 10/20/2023
-
Fri, 20 Oct 2023 House: Ch. SL 2023-141
Bill Summaries:
-
Bill H 415 (2023-2024)Summary date: Oct 23 2023 - View Summary
-
Bill H 415 (2023-2024)Summary date: Sep 22 2023 - View Summary
Senate amendment to the 3rd edition adds the following.
Provides that if H125 (NC Health & Human Services Workforce Act) becomes law, then GS 90-293 is amended by amending the definition of the practice of audiology to prohibit audiologists from performing complex cerumen removal, which includes instances where cerumen is impacted to the point that removal requires the use of anesthesia or micro-instrumentation (was, the use of a microscope is allowed as part of audiological practice but must not be used when cerumen is impacted to the point that it would require the use of anesthesia in conjunction with microscopes or micro-instrumentation).
Makes conforming changes to the act's long title.
-
Bill H 415 (2023-2024)Summary date: Jun 22 2023 - View Summary
House committee substitute to the 2nd edition makes the following changes. Amends new GS 90-113.151 (truth in marketing) (c) and (d), which set out unlawful activities by specifying in each listed act that it must be done knowingly and with the intent to defraud any person. Makes it unlawful to knowingly make a materially false or misleading statement (was, to suggest or imply) that a relationship with a treatment provider exists, with the intent to defraud another person, unless the treatment provider has provided express, written consent to indicate such a relationship. Makes conforming changes
Amends new GS 90-113.152 (patient brokering and kickbacks) to also require that the specified unlawful acts be done knowingly (was, liability under the statute exists regardless of whether the person has actual knowledge of this statute or specific intent to commit a violation of the statute).
-
Bill H 415 (2023-2024)Summary date: Apr 4 2023 - View Summary
House committee substitute to the 1st edition makes the following changes. Amends new GS 90-113.151(a) (truth in marketing) to specify that the listing in marketing materials of the name and brand apply to residence, provider site, or facility (was, just treatment facility). Amends GS 90-113.151(b) to also require operators of a recovery residence or licensed residential treatment facility that also provides separately licensed outpatient substance abuse disorder services to clearly disclose the nature of those relationships, in addition to other labeling and disclosure obligations already listed. Makes organizational and technical changes.
-
Bill H 415 (2023-2024)Summary date: Mar 20 2023 - View Summary
Enacts new Article 5H to GS Chapter 90. Names the act “The Stop Addiction Fraud Ethics Act of 2023” or the “SAFE Act of 2023.” Defines the following terms: recovery residence (a shared living environment that is, or is intended to be, free from alcohol and illicit drug use and centered on peer support and connection to services that promote sustained recovery from substance use disorders), treatment facility (a facility or program that is, or is required to be, licensed, accredited, or certified to provide substance use disorder treatment services), and treatment provider (a person or entity that is, or is required to be, licensed, accredited, or certified to provide substance use disorder treatment services, including treatment facilities). Also defines referral and patient.
Directs a treatment provider, treatment facility, recovery residence, or third party providing services to any treatment provider, treatment facility, or recovery residence to produce accurate and complete advertising materials containing the following information in plain, easy to understand language: (1) the types and methods of services provided or used, and information about where they are provided, using the categories of treatment and levels of care described in the American Society of Addiction Medicine, Patient Placement Criteria, Revised; (2) the average lengths of stay at the treatment facility during the preceding 12-month period for each of the categories of treatment and levels of care referenced above; (3) the treatment facility’s name and brand; and (4) a brief summary of any financial relationships between the treatment facility and any publisher of marketing or advertising.
Requires each operator of a recovery residence or licensed residential treatment facility that also provides separately licensed outpatient substance use disorder services to clearly: (1) label each facility and service separately in any marketing or advertising material published or provided by the operator and (2) distinguish the recovery residence or licensed residential treatment facility from the licensed outpatient substance use disorder services.
Makes the following two acts committed by any treatment provider, treatment facility, recovery residence, or third party providing services to any treatment provider, treatment facility, or recovery residence an unfair or deceptive trade practice under GS 75-1.1 (State Consumer Protection Act) and a Class G felony for knowing violations: (1) making a materially false or misleading statement, or providing false or misleading information, about the nature, identity, or location of substance use disorder treatment services or a recovery residence in advertising materials, on a call line, on an internet website, or in any other marketing materials; (2) making a false or misleading statement about the treatment provider's status as an in-network or out-of-network provider; the credentials, qualifications, or experiences of persons providing treatment or services; or the rate of recovery or success in providing services. Each violation constitutes a separate offense.
Makes the following four acts committed by any person or entity an unfair or deceptive trade practice under GS 75-1.1 and a Class G felony for knowing violations: (1) to provide, or direct any other person or entity to provide, false or misleading information about the identity of, or contact information for, any treatment provider; (2) to include false or misleading information about the internet website of any treatment provider, or to surreptitiously direct or redirect the reader to another internet website; (3) to suggest or imply that a relationship with a treatment provider exists, unless the treatment provider has provided express, written consent to indicate such a relationship; (4) to make a materially false or misleading statement about substance use disorder treatment services. Each violation constitutes a separate offense.
Makes it a Class G felony for any person or entity, including a treatment provider, treatment facility, recovery residence, or third party providing services to any of these persons or entities to engage in any of the following acts of patient brokering or kickbacks: (1) offer or pay anything of value, directly or indirectly, in cash or in kind, or engage in any split-fee arrangement, in any form whatsoever, to induce the referral of a patient or patronage to or from a treatment provider or laboratory; (2) solicit or receive anything of value, directly or indirectly, in cash or in kind, or engage in any split-fee arrangement, in any form whatsoever, in return for referring a patient or patronage to or from a treatment provider or laboratory; (3) solicit or receive anything of value, directly or indirectly, in cash or in kind, or engage in any split-fee arrangement, in any form whatsoever, in return for the acceptance or acknowledgment of treatment from a health care provider or health care facility; (4) aid or abet any of the above conduct in this paragraph. Specifies that the following are not considered unlawful patient brokering or kickbacks: (1) any discount, payment, waiver of payment, or payment practice that is expressly authorized by 42 U.S.C. § 1320a-7b(b)(3) (pertaining to lawful financial transactions in federal health care programs) or any regulation adopted under that statute; (2) a reasonable contingency management technique or other reasonable motivational incentive that is part of the treatment provided by an accredited, licensed, or certified treatment provider.
Exempts licensed general hospitals and hospital authorities from the Act.
Effective January 1, 2024, and applies to offenses committed on or after that date.
Identical to S 361, filed 3/22/23.